Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: A comparison of the MRC ALL97/99 and UKALL2003 trials

Journal of Clinical Oncology

Volumn 31, Issue 27, 2013, Pages 3389-3396

  Moorman, Anthony V ^a   Robinson, Hazel ^a   Schwab, Claire ^a   Richards, Sue M ^b   Hancock, Jeremy ^d   Mitchell, Christopher D ^c   Goulden, Nicholas ^e   Vora, Ajay ^f   Harrison, Christine J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d NORTH BRISTOL NHS TRUST   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; METHOTREXATE; TRANSCRIPTION FACTOR RUNX1; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME 21; COHORT ANALYSIS; EVENT FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HYPERSENSITIVITY; INTRACHROMOSOMAL AMPLIFICATION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUROPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATITIS; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK REDUCTION; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; UNITED KINGDOM; CYTOGENETICS; GENE TRANSLOCATION; GENETICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK FACTOR; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHROMOSOMES, HUMAN, PAIR 21; CYTOGENETICS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC;

EID: 84887513571     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.48.9377     Document Type: Article

References (28)

1. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011
2. Pui CH, Carroll WL, Meshinchi S, et al: Biology, risk stratification, and therapy of pediatric acute leukemias: An update. J Clin Oncol 29:551-565, 2011
3. Moorman AV: The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev 26:123-135, 2012
4. Moorman AV, Ensor HM, Richards SM, et al: Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: Results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 11:429-438, 2010
5. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166-178, 2006
6. Mitchell C, Payne J, Wade R, et al: The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: Results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99. Br J Haematol 146:424-436, 2009
7. Rand V, Parker H, Russell LJ, et al: Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood 117:6848-6855, 2011
8. Harewood L, Robinson H, Harris R, et al: Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: A study of 20 cases. Leukemia 17:547-553, 2003
9. Soulier J, Trakhtenbrot L, Najfeld V, et al: Amplification of band q22 of chromosome 21, including AML1, in older children with acute lymphoblastic leukemia: An emerging molecular cytogenetic subgroup. Leukemia 17:1679-1682, 2003
10. Robinson HM, Harrison CJ, Moorman AV, et al: Intrachromosomal amplification of chromosome 21 (iAMP21) may arise from a breakage-fusionbridge cycle. Genes Chromosomes Cancer 46:318-326, 2007
11. Strefford JC, van Delft FW, Robinson HM, et al: Complex genomic alterations and gene expression in acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Proc Natl Acad Sci U S A 103:8167-8172, 2006
12. Sinclair PB, Parker H, An Q, et al: Analysis of a breakpoint cluster reveals insight into the mechanism of intrachromosomal amplification in a lymphoid malignancy. Hum Mol Genet 20:2591-2602, 2011
13. Harrison CJ: Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol 144:147-156, 2009
14. Harrison CJ, Haas O, Harbott J, et al: Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: Recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfü rt-Mü nsterstudy group. Br J Haematol 151: 132-142, 2010
15. Moorman AV, Richards SM, Robinson HM, et al: Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 109:2327-2330, 2007
16. Mitchell CD, Richards SM, Kinsey SE, et al: Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: Results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129:734-745, 2005
17. Vora A, Goulden N, Wade R, et al: Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): A randomised controlled trial. Lancet Oncol 14:199-209, 2013
18. Vora A, Mitchell CD, Lennard L, et al: Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: A randomised trial. Lancet 368:1339-1348, 2006
19. Qureshi A, Mitchell C, Richards S, et al: Asparaginase-related venous thrombosis in UKALL 2003: Re-exposure to asparaginase is feasible and safe. Br J Haematol 149:410-413, 2010
20. Chessells JM, Richards SM, Bailey CC, et al: Gender and treatment outcome in childhood lymphoblastic leukemia: Report from the MRC UKALL trials. Br J Haematol 89:364-372, 1995
21. van der Velden VH, Cazzaniga G, Schrauder A, et al: Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia 21: 604-611, 2007
22. Schwab CJ, Chilton L, Morrison H, et al: Genes commonly deleted in childhood B-cell precursor ALL: Association with cytogenetics and clinical features. Haematologica 98:1081-1088, 2013
23. Nachman JB, Sather HN, Sensel MG, et al: Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338:1663-1671, 1998
24. Attarbaschi A, Mann G, Panzer-Grümayer R, et al: Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: The Austrian and German Acute Lymphoblastic Leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J Clin Oncol 26:3046-3050, 2008
25. Pé rez-Vera P, Montero-Ruíz O, Frías S, et al: Multiple copies of RUNX1: Description of 14 new patients, follow-up, and a review of the literature. Cancer Genet Cytogenet 180:129-134, 2008
26. Cooley LD, Chenevert S, Shuster JJ, et al: Prognostic significance of cytogenetically detected chromosome 21 anomalies in childhood acute lymphoblastic leukemia: A Pediatric Oncology Group study. Cancer Genet Cytogenet 175: 117-124, 2007
27. Schultz KR, Bowman WP, Aledo A, et al: Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group study. J Clin Oncol 27:5175-5181, 2009
28. Pui CH, Mullighan CG, Evans WE, et al: Pediatric acute lymphoblastic leukemia: Where are we going and how do we get there? Blood 120:1165-1174, 2012